Cargando…

A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis

BACKGROUND: Receptor-interacting protein kinase 1 (RIPK1) is a key mediator of inflammation through cell death and proinflammatory cytokine production. This multicenter, randomized, double-blind (sponsor-unblinded), placebo-controlled, experimental medicine study evaluated the safety, pharmacokineti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weisel, Kathleen, Berger, Scott, Thorn, Katie, Taylor, Peter C., Peterfy, Charles, Siddall, Hilary, Tompson, Debra, Wang, Susanne, Quattrocchi, Emilia, Burriss, Susan W., Walter, Jochen, Tak, Paul Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962407/ https://www.ncbi.nlm.nih.gov/pubmed/33726834 http://dx.doi.org/10.1186/s13075-021-02468-0

Ejemplares similares

A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis
por: Weisel, Kathy, et al.
Publicado: (2021)

Comparison of the Pharmacokinetics of RIPK1 Inhibitor GSK2982772 in Healthy Western and Japanese Subjects
por: Tompson, Debra J., et al.
Publicado: (2020)

Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers
por: Weisel, Kathleen, et al.
Publicado: (2017)

Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772
por: Tompson, Debra J., et al.
Publicado: (2021)

Development of a Once-Daily Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology
por: Tompson, Debra, et al.
Publicado: (2022)

Response to Inhibition of Receptor‐Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo‐Controlled Study
por: Weisel, Kathleen, et al.
Publicado: (2020)

Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study
por: Schwartzbach, Caryl J., et al.
Publicado: (2016)

Intranasal GSK2245035, a Toll-like receptor 7 agonist, does not attenuate the allergen-induced asthmatic response in a randomized, double-blind, placebo-controlled experimental medicine study
por: Siddall, Hilary, et al.
Publicado: (2020)

Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial
por: Taylor, Peter C, et al.
Publicado: (2011)

The Role of RIPK1 and RIPK3 in Cardiovascular Disease
por: DeRoo, Elise, et al.
Publicado: (2020)

Ripk1 and haematopoiesis: a case for LUBAC and Ripk3
por: Annibaldi, Alessandro, et al.
Publicado: (2018)

GSK840 Alleviates Retinal Neuronal Injury by Inhibiting RIPK3/MLKL-Mediated RGC Necroptosis After Ischemia/Reperfusion
por: Feng, Yanlin, et al.
Publicado: (2023)

Identification of MYC as an antinecroptotic protein that stifles RIPK1–RIPK3 complex formation
por: Seong, Daehyeon, et al.
Publicado: (2020)

MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study
por: Peterfy, Charles, et al.
Publicado: (2016)

RIPK1 blocks T cell senescence mediated by RIPK3 and caspase-8
por: Imanishi, Takayuki, et al.
Publicado: (2023)

Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate
por: Cohen, Stanley B, et al.
Publicado: (2010)

Primary cilia suppress Ripk3-mediated necroptosis
por: Kieckhöfer, Emilia, et al.
Publicado: (2022)

TNF can activate RIPK3 and cause programmed necrosis in the absence of RIPK1
por: Moujalled, D M, et al.
Publicado: (2013)

HIV-1 protease cleaves the serine-threonine kinases RIPK1 and RIPK2
por: Wagner, Roland N., et al.
Publicado: (2015)

RIPK1/RIPK3 promotes vascular permeability to allow tumor cell extravasation independent of its necroptotic function
por: Hänggi, Kay, et al.
Publicado: (2017)

TRAF6 regulates the abundance of RIPK1 and inhibits the RIPK1/RIPK3/MLKL necroptosis signaling pathway and affects the progression of colorectal cancer
por: Lin, Penghang, et al.
Publicado: (2023)

Necroptosis: Fifty shades of RIPKs
por: Ichim, Gabriel, et al.
Publicado: (2014)

RIPK1 or RIPK3 deletion prevents progressive neuronal cell death and improves memory function after traumatic brain injury
por: Wehn, Antonia Clarissa, et al.
Publicado: (2021)

RIPK1–RIPK3–MLKL-Associated Necroptosis Drives Leishmania infantum Killing in Neutrophils
por: Barbosa, Laiana A., et al.
Publicado: (2018)

TRADD regulates perinatal development and adulthood survival in mice lacking RIPK1 and RIPK3
por: Dowling, John P., et al.
Publicado: (2019)

Ubiquitylation of RIPK3 beyond-the-RHIM can limit RIPK3 activity and cell death
por: Frank, Daniel, et al.
Publicado: (2022)

RIPK1 and RIPK3 inhibitors: potential weapons against inflammation to treat diabetic complications
por: Ke, Dan, et al.
Publicado: (2023)

RIPK1-RIPK3-MLKL-dependent necrosis promotes the aging of mouse male reproductive system
por: Li, Dianrong, et al.
Publicado: (2017)

Execution of RIPK3-regulated necrosis
por: Cai, Zhenyu, et al.
Publicado: (2014)

Advances in RIPK1 kinase inhibitors
por: Chen, Lu, et al.
Publicado: (2022)

Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death
por: Moriwaki, K, et al.
Publicado: (2015)

Ubiquitination of RIPK1 suppresses programmed cell death by regulating RIPK1 kinase activation during embryogenesis
por: Zhang, Xixi, et al.
Publicado: (2019)

Catecholamine Surges Cause Cardiomyocyte Necroptosis via a RIPK1–RIPK3-Dependent Pathway in Mice
por: Wu, Penglong, et al.
Publicado: (2021)

Investigation on the expression regulation of RIPK1/RIPK3 in the retinal ganglion cells (RGCs) cultured in high glucose
por: Gao, Sheng, et al.
Publicado: (2021)

RIPK1 and RIPK3 regulate TNFα-induced β-cell death in concert with caspase activity
por: Contreras, Christopher J., et al.
Publicado: (2022)

Human ZBP1 induces cell death‐independent inflammatory signaling via RIPK3 and RIPK1
por: Peng, Ruoshi, et al.
Publicado: (2022)

Inhibition of RIPK1 kinase does not affect diabetes development: β-Cells survive RIPK1 activation
por: Takiishi, Tatiana, et al.
Publicado: (2023)

AC-CUTE: An Open-Label Study to Evaluate Progression of Structural Joint Damage and Inflammation in Subjects with Moderate to Severe Rheumatoid Arthritis
por: Bird, Paul, et al.
Publicado: (2018)

Nuclear RIPK3 and MLKL contribute to cytosolic necrosome formation and necroptosis
por: Weber, Kathrin, et al.
Publicado: (2018)

Elevated RIPK3 correlates with disease burden in myelofibrosis
por: Dill, Veronika, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_40cbtds2dqi6q7p5n3hqomq1cu